# Karyopharm Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Company Progress
Canonical URL: https://biopharmsignal.com/news/KPTI/karyopharm-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-recent-company-progress
Ticker: KPTI
Company: Karyopharm Therapeutics
Source: Karyopharm Therapeutics
Published: 2026-02-12 12:30 EST
Original Source URL: https://investors.karyopharm.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-cc27221e) — Source: Karyopharm Therapeutics
- 2026-06-03 20:15 EST — [Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026](https://biopharmsignal.com/news/KPTI/karyopharm-to-participate-in-webcast-featuring-endometrial-cancer-key-opinion-leader-on-june-8-2026) — Source: Karyopharm Therapeutics
- 2026-06-02 14:02 EST — [Karyopharm's Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis Selected for Late-Breaking Oral Presentation at EHA 2026](https://biopharmsignal.com/news/KPTI/karyopharm-s-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-selected-for-late-breaking-oral-presentation-at-eha-2026) — Source: Karyopharm Therapeutics
- 2026-06-02 12:59 EST — [Karyopharm to Present Results from Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis in Late-Breaking Oral Presentation at ASCO 2026 with Simultaneous Publication in the Journal of Clinical Oncology](https://biopharmsignal.com/news/KPTI/karyopharm-to-present-results-from-phase-3-sentry-trial-of-selinexor-plus-ruxolitinib-in-myelofibrosis-in-late-breaking-oral-presentation-at-asco-2026-with-simultaneous-publication-in-the-journal-of-clinical-oncology) — Source: Karyopharm Therapeutics
- 2026-06-01 20:05 EST — [Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/KPTI/karyopharm-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: Karyopharm Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)